Lv4
446 积分 2021-10-08 加入
Mirvetuximab soravtansine plus carboplatin in folate receptor alpha-expressing recurrent platinum-sensitive ovarian cancer
27天前
已关闭
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial
2个月前
已完结
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
3个月前
已完结
The impact of gastrointestinal tract resection in oral drug absorption
6个月前
已关闭
Enteral Drug Absorption in Patients with Short Small Bowel
6个月前
已完结
A mini-overview of antibody-drug conjugates in platinum-resistant ovarian cancer: A preclinical and clinical perspective
8个月前
已完结
CA-125 criteria for response evaluation in ovarian cancer
10个月前
已完结
PICCOLO: An open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression (300)
10个月前
已完结
A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy
11个月前
已完结
皖公网安备34019202002308
